Preparation and characterization of magnetic nanoparticles containing Fe₃O₄-dextran-anti-β-human chorionic gonadotropin, a new generation choriocarcinoma-specific gene vector

Cai Jingting¹,², Liu Huining¹, Zhang Yi¹
¹Department of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; ²Department of Gynecological Oncology, Hunan Tumor Hospital, Changsha, Hunan, People’s Republic of China

Objective: To evaluate the feasibility of using magnetic iron oxide (Fe₃O₄)-dextran-anti-β-human chorionic gonadotropin (HCG) nanoparticles as a gene vector for cellular transfections.

Study design: Fe₃O₄-dextran-anti-β-HCG nanoparticles were synthesized by chemical coprecipitation. The configuration, diameter, and iron content of the nanoparticles were detected by transmission electron microscopy (TEM), light scatter, and atomic absorption spectrophotometry. A3-(4,5)-dimethylthiazol-(2,5)-yl)-3,5-di-phenyltetrazoliumromide assay was used to evaluate the cytotoxicity of Fe₃O₄-dextran-anti-β-HCG nanoparticles. Enzyme-linked immunosorbent assay and indirect immunofluorescence were used to evaluate immunoreactivity. The efficiency of absorbing DNA and resisting deoxyribonuclease I (DNase I) digestion when bound to Fe₃O₄-dextran-anti-β-HCG nanoparticles was examined by agarose gel electrophoresis. The ability of Fe₃O₄-dextran-anti-β-HCG nanoparticles to absorb heparanase antisense oligodeoxynucleotides (AS-ODN) nanoparticles in different cell lines was evaluated by flow cytometry. The tissue distribution of heparanase AS-ODN magnetic nanoparticles in choriocarcinoma tumors transplanted in nude mice was detected by atomic absorption spectrophotometry.

Results: TEM demonstrated that the shape of nanoparticles is irregular. Light scatter revealed nanoparticles with a mean diameter of 75.5 nm and an iron content of 37.5 µg/mL. No cytotoxicity was observed when the concentration of Fe₃O₄-dextran-anti-β-HCG nanoparticles was <37.5 µg/mL. Fe₃O₄-dextran nanoparticles have a satisfactory potential to combine with β-HCG antibody. Agarose gel electrophoresis analysis of binding experiments showed that after treatment with sodium periodate, Fe₃O₄-dextran-anti-β-HCG nanoparticles have a satisfactory potential to absorb DNA, and the protection experiment showed that nanoparticles can effectively protect DNA from DNase I digestion. Aldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticles can transfect reporter genes, and the transfection efficiency of these nanoparticles is greater than that of liposomes (P < 0.05). Fe₃O₄-dextran-anti-β-HCG nanoparticles can concentrate in choriocarcinoma cells and in transplanted choriocarcinoma tumors.

Conclusions: The results confirm that Fe₃O₄-dextran-anti-β-HCG nanoparticles have potential as a secure, effective, and choriocarcinoma-specific targeting gene vector.

Keywords: magnetic nanoparticles, Fe₃O₄-dextran-anti-β-HCG, choriocarcinoma, targeting vector, gene vector

Gene therapy modifies gene expression for therapeutic gain. Over the last two decades, gene therapy research has moved from preclinical to clinical studies for many diseases, ranging from single-gene disorders, such as cystic fibrosis and Duchene muscular dystrophy, to multigenic diseases, such as cancer.
In most gene therapy studies, a ‘corrected’ therapeutic gene is inserted into the genome to replace an ‘abnormal’ disease-causing gene. A vector (ie, a carrier) must be used to deliver the therapeutic gene to the patient’s target cells. The most common vectors are viruses, but viral vectors are often toxic or immunogenic and make it difficult to verify successful infection of the targeted cells.

An ideal gene delivery system should be stable, biocompatible, nontoxic, cost-effective, and capable of transferring exogenous, highly anionic genetic materials (ie, DNA, antisense oligodeoxynucleotides [AS-ODNs], short interfering ribonucleic acids [RNAs]) into tissue-specific sites. A primary goal of gene therapy is to target vectors and the genes of interest efficiently to specific cell types. Recent advances in nanoparticle technology have yielded new types of gene vectors.

Magnetic iron oxide (Fe₃O₄) nanoparticles are considered ideal gene vectors because they are simple to manufacture, have diameters of <10 nm, are able to absorb a significant amounts of DNA, demonstrate limited cellular toxicity, and can be guided to specific sites via magnets. In addition, to improve biocompatibility, iron oxide nanoparticles can be embedded in various macromolecules, such as polysaccharides and proteins. However, human organs such as liver, spleen, and lymph (among others) are infused with a reticuloendothelial system and have the ability to passively absorb nanoparticles through phagocytosis. Because β-human chorionic gonadotropin (HCG) is expressed only in choriocarcinomas, anti-β-HCG monoclonal antibody were attached to magnetic particles to allow the nanoparticles to target the tissues of interest.

In this study, nanometer-sized dextran-coated iron oxide particles modified with an anti-β-HCG monoclonal antibody were synthesized, and the feasibility of using Fe₃O₄-dextran-anti-β-HCG as a gene vector was tested.

Material and methods

Materials

All reagents used for nanoparticle synthesis were commercial products. Dextran (40,000 MW; T-40), deoxyribonuclease I (DNase I), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich Corporation (St. Louis, MO). Lipofectamine™2000 was purchased from Invitrogen Corporation (Carlsbad, CA). Mouse anti-human β-HCG monoclonal antibody was purchased from Worl Biotechnology (Shanghai, China). Goat anti-mouse immunoglobulin G/fluorescein isothiocyanate (IgG/FITC) and goat anti-mouse IgG/horseradish peroxidase (HRP) were purchased from Sigma-Aldrich Corporation (Shiga, Japan). Analytical grade chemicals (FeCl₃·6H₂O, FeCl₂·4H₂O) were obtained from local suppliers. All aqueous solutions were prepared using distilled water and filtered through 0.22-mm membranes.

JEG-3 and JAR human choriocarcinoma cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA). RL95-2, Hela, HepG2, and Lovo cell lines were supplied by the cell center of Central South University (Changsha, China).

Female BALB/c nude mice (4 weeks old) were supplied and fed by the animal division of Central South University.

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) AS-ODN was synthesized by Shanghai Sangon Biological Engineering Technology and Services Company Ltd (Shanghai, China). The GAPDH AS-ODN sequence was 5′-GAC CTT CAC CAT CTT GTC TA-3′, with a 5′ terminal FITC group including some phosphorothioated nucleotides. Oligonucleotides were diluted to 100 µmol/L and stored at −20°C.

Cell culture studies

JEG-3, JAR, RL95-2, Hela, HepG2, and Lovo cell lines were cultured in Roswell Park Memorial Institute (RPMI) medium (Invitrogen) supplemented with 10% fetal calf serum.

Preparation and physical characterization of magnetic Fe₃O₄-dextran-anti-β-HCG nanoparticles

Preparation of nanoparticles

Fe₃O₄-dextran-anti-β-HCG nanoparticles were prepared as described by Xia et al.² Dextran (5 g), FeCl₃·6H₂O (0.552 g), and FeCl₂·4H₂O (0.45 g) were dispersed in 10 mL water. The mixture was titrated to alkaline by 10 mL of 5 mol/L ammonia and quickly heated to 60°C, with magnetic stirring. After 30 min, the suspension was neutralized with acetic acid. Aggregates were removed by centrifugation for 10 min. The dextran-coated iron oxide nanoparticles were separated from unbound dextran by magnetic separator and eluted with 10 mL sodium acetate (pH 6.5). The dextran-coated iron oxide suspension was oxidized with sodium periodate (NaIO₄) with magnetic stirring in the dark at 4°C for 1 h to drive aldehyde termination. The solution was dialyzed while under magnetic stirring. Then, 100 µg mouse anti-human β-HCG monoclonal antibody was mixed with 1 mL aldehyde dextran-coated iron oxide nanoparticle solution. The solution was kept in the dark at 4°C for 24 h.
and then blocked by 50 µL 10% wt/vol BSA. To improve stability, 1 mol/L sodium borohydride (NaBH₄) was added to the compound at 4°C for 3 h and stirred. Finally, the suspension was centrifuged for 20 min at 13,000 rpm, repeated three times. The final product was dispersed in 1 mL sodium perborate (NaBO₃) (pH 8.5) and preserved at 4°C.

**Morphological determination**
The Fe₃O₄-dextran-anti-β-HCG nanoparticles solution was titrated with a copper wire. After drying, morphological structure was determined by CM120 transmission electron microscopy (TEM) (Philips, Eindhoven, The Netherlands).

**Effective diameter determination**
Fe₃O₄-dextran-anti-β-HCG nanoparticles were dispersed in high-purity water using ultrasound vibration and placed into a color matching cup. The effective diameter was determined using a Mastersizer 2000 Laser Particle Size Analyzer (Malvern Instruments, Malvern, UK).

**Evaluation of iron content**
Iron content was determined by atomic absorption Spectra-30 Photometer (Varian Instruments, Palo Alto, CA).

**Effect of Fe₃O₄-dextran-anti-β-HCG nanoparticles on cells**

**Toxicity of Fe₃O₄-dextran-anti-β-HCG nanoparticle**
JEG-3 cells were seeded in 96-well plates (5000 cells/well) in media containing various concentrations of Fe₃O₄-dextran-anti-β-HCG nanoparticles (0, 18.75, 30.0, 37.5, 56.25, and 75 µg/mL). After 24 h, MTT (Sigma) was added and incubated for 4 h. Cells were washed with phosphate-buffered saline (PBS) and stained with purple formazan solubilized in 100% dimethyl sulfoxide. Absorbance was read at 570 nm. The inhibitory rate of Fe₃O₄-dextran-anti-β-HCG nanoparticles was calculated as (OD₅₇₀ control group− OD₅₇₀ experimental group)/OD₅₇₀ control group).

**Immunological features of Fe₃O₄-dextran-anti-β-HCG nanoparticles**

**Enzyme-linked immunosorbent assays for Fe₃O₄-dextran-anti-β-HCG nanoparticles**
JEG-3 cells were seeded in 96-well plates (5000 cells/well). Aldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle, nonaldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle (anti-β-HCG monoclonal antibody was mixed with nonoxidized dextran-coated iron oxide nanoparticles), and anti-β-HCG monoclonal antibody solutions (at 10, 50, 80, 100, or 150 µg/mL anti-β-HCG monoclonal antibody) were titrated into the wells (100 µL/well) which were incubated for 1 h at 37°C. Dextran-coated iron oxide nanoparticles served as a control. After washing two times, goat antimouse IgG/HRP (diluted 1:2000) was added into each well and wells were incubated at 37°C for 1 h. Solutions were prepared by addition of 3,3′,5,5′-tetramethylbenzidine peroxidase, for 15–20 min at 37°C, and the reactions were stopped by addition of 2M H₂SO₄ (50 µL/well). Optical density (OD) was read at 492 nm immediately after stopping the reaction in an ELX808 Ultra Microplate Reader (Bio-Tek, Winooski, VT). All samples were prepared in triplicate. The percent transfection was calculated as OD anti-β-HCG monoclonal antibody activity of aldehyde or nonaldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle/OD anti-β-HCG monoclonal antibody × 100.

**Indirect immunofluorescence assay for Fe₃O₄-dextran-anti-β-HCG nanoparticles**
JEG-3 cells were seeded onto slides and incubated in culture dishes for 48 h. The cells were then incubated with aldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle solution, nonaldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle solution, and anti-β-HCG monoclonal antibody solution which contained 100 µg/mL anti-β-HCG monoclonal antibody at 4°C for 30 min. JEG-3 cells were then cultured for another 30 min, fixed using paraformaldehyde, treated with trinitrotoluene, and incubated with goat antimouse IgG/FITC at 37°C for 30 min. Slides were sealed with glycerin, and images were observed at 400 by fluorescence microscopy (Axiolab; Carl Zeiss Shanghai Co Ltd, Guangzhou, China).

**Evaluation of Fe₃O₄-dextran-anti-β-HCG nanoparticles as gene vectors**
Preparation of Fe₃O₄-dextran-anti-β-HCG-GAPDH AS-ODN mixtures
Mouse antihuman β-HCG monoclonal antibody (10 µg) and GAPDH AS-ODN (20 µL in 100 µmol/L) were mixed with 100 µL aldehyde or nonaldehyde dextran-coated iron oxide nanoparticles. Following incubation in the dark at 4°C for 24 h, the mixture was blocked by 5 µL of 10% wt/vol bovine serum albumin (BSA). To improve stability, 1 mol/L NaBH₄ was added to the mixture at 4°C and stirred for 3 h. Finally, the suspension was centrifuged for 20 min at 13,000 rpm, the supernatant removed, and dispersed again with 100 µL NaBO₃ (pH 8.5). This centrifugation and wash step were repeated three times.
Electrophoretic assessment of nanoparticle complexes

Aldehyde Fe\(_3\)O\(_4\)-dextran-anti-β-HCG-GAPDH AS-ODN, nonaldehyde Fe\(_3\)O\(_4\)-dextran-anti-β-HCG-GAPDH AS-ODN, and GAPDH AS-ODN (20 µmol/L) were separated by gel electrophoresis and visualized by ethidium bromide staining. Samples were analyzed using GeneScan Analysis software and GeneScan Genotyper software (Applied Biosystems, Foster City, CA). Aldehyde Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticle solution served as a control.

Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticles protect DNA from DNase I

Aldehyde Fe\(_3\)O\(_4\)-dextran-anti-β-HCG-GAPDH AS-ODN, nonaldehyde Fe\(_3\)O\(_4\)-dextran-anti-β-HCG-GAPDH AS-ODN, and GAPDH AS-ODN (20 µmol/L) were subjected to DNase I at 37°C for 1 h. Products were identified by gel electrophoresis and visualized by ethidium bromide staining. Results were obtained by GeneScan Analysis software and GeneScan Genotyper software (Applied Biosystems).

Efficiency of Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticles as gene vector

JEG-3 cells were seeded in six-well plates in culture media containing Fe\(_3\)O\(_4\)-dextran-anti-β-HCG-GAPDH AS-ODN/FITC compounds (20-µmol/L AS-ODN, 37.5-µg/mL Fe\(^{3+}\)), Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticles (37.5-µg/mL Fe\(^{3+}\)), GAPDH AS-ODN/FITC (20-µmol/L AS-ODN), and liposome-GAPDH AS-ODN/FITC compounds (20-µmol/L AS-ODN). Pure culture media served as controls. Following transfection, cells were cultured for 24 h, digested with trypsin (0.25%), and washed three times with PBS (centrifuged for 5 min at 1000 rpm to remove free fluorescence). Fluorescence intensity (10^6 cells) was measured by flow cytometry.

Absorption of Fe\(_3\)O\(_4\)-dextran-anti-β-HCG-GAPDH AS-ODN in different cell type

JEG-3, JAR, RL95-2, Hela, HepG2, and Lovo cells were seeded in six-well plates and transfected with Fe\(_3\)O\(_4\)-dextran-anti-β-HCG-GAPDH AS-ODN/FITC compounds (20-µmol/L AS-ODN, 37.5-µg/mL Fe\(^{3+}\)). Fluorescence intensity was measured using flow cytometry as described.

Distribution of Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticles in nude mice

Cultured JEG-3 cells were harvested and resuspended in naive RPMI medium at 4–6 x 10^6 cells/mL, and 100 µL were immediately injected into the flank of eight nude mice. When tumor diameter reached ~8–10 mm, Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticle solution (0.5 mL/mouse, 1.5 mg/mL Fe\(^{3+}\)) was injected into tail veins of eight mice; the hypodermal tumor of four mice (group I) were treated with a 12,000 gauss, 1-cm-diameter magnetic stick, and four mice (group II) were not treated. Dextran-coated iron oxide nanoparticle solution (0.5 mL/mouse, 1.5 mg/mL Fe\(^{3+}\)) was also injected to four mice (group III) through the tail vein. After 30 min, 100 mg of tissue was harvested from heart, liver, spleen, lung, kidney, and choriocarcinoma hypodermal tumors of all mice and digested (nitric acid:perchloric acid, 4:1). Iron content was measured by atomic absorption using a Spectra-30 Photometer.

Statistical analysis

Statistical significance was assessed using Student’s t-test or analysis of variance (ANOVA) (one-way ANOVA followed by Dunnett’s test) using SAS (SAS Institute, Cary, NC). Differences between means were considered significant at P < 0.05.

Results

Morphology and diameter of Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticles

Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticle solution is atramentous and transparent. Using TEM, nanoparticles of uniform size and irregular shape (Figure 1) were observed. The average diameter was 75.5 nm (range = 33.7–84.7 nm).

The iron content of Fe\(_3\)O\(_4\)-dextran-anti-β-HCG nanoparticles is 37.5 µg/mL.

Figure 1 Transmission electron micrograph of magnetic iron oxide (Fe\(_3\)O\(_4\))-dextran-anti-β-HCG nanoparticles.

Abbreviations: HCG, human chorionic gonadotropin.
Toxicity of Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles

As shown in Table 1, the inhibitory rate of nanoparticles at 56.25 and 75 µg/mL is higher than control ($P < 0.05$). In contrast, a significant difference was not observed between nanoparticle concentrations at 18.75, 30, or 37.5 µg/mL and control ($P > 0.05$).

Enzyme-linked immunosorbent assay for Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles

The transfection efficiency of anti-β-HCG monoclonal antibody activity in aldehyde Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticle is >85%, whereas the transfection rate of anti-β-HCG monoclonal antibody activity in nonaldehyde Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticle is ∼13% ($P < 0.05$) (Table 2).

Indirect immunofluorescence assay for Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles

Upon treatment with aldehyde Fe$_3$O$_4$-dextran-anti-β-HCG/FITC nanoparticle solution, JEG-3 cells surrounded by fluorescent (Figure 2A) were noted. A similar result was obtained with anti-β-HCG antibody (Figure 2B). Together, these data suggest that Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles bind with JEG-3 cells in a manner similar to anti-β-HCG antibody. Nonaldehyde Fe$_3$O$_4$-dextran-anti-β-HCG/FITC nanoparticles cannot combine with JEG-3 cells because there are no fluorescent substances on JEG-3 cells (Figure 2C).

Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles as a gene vector

DNA in nonaldehyde Fe$_3$O$_4$-dextran-anti-β-HCG-GAPDH AS-ODN complexes migrate in agarose gels (Figure 3, third track), similar to migration of simple GAPDH AS-ODN (second track). This indicates that nonaldehyde Fe$_3$O$_4$-dextran nanoparticles cannot combine with GAPDH AS-ODN. After oxidation with NaIO$_4$, aldehyde Fe$_3$O$_4$-dextran nanoparticles are able to combine with GAPDH AS-ODN, so the DNA in aldehyde Fe$_3$O$_4$-dextran-anti-β-HCG-GAPDH AS-ODN complexes is retained in the loading well (Figure 3, fourth track). On the other hand, there is no DNA in Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles, hence the compounds migrate either in the fifth track or in the loading well.

Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles protect DNA from DNase I

The absence of a DNA band in second and third tracks indicates that the DNA in nonaldehyde Fe$_3$O$_4$-dextran-anti-β-HCG-GAPDH AS-ODN complexes and simple GAPDH AS-ODN is digested by DNase I. In contrast, DNA in the aldehyde Fe$_3$O$_4$-dextran-anti-β-HCG-GAPDH AS-ODN complexes is retained in the loading well of fourth track, indicating that Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles protect DNA from DNase I digestion (Figure 4).

Efficiency of Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticle as gene vector

The fluorescence intensity of group IV in JEG-3 cells is higher than that of groups I, II, III, and V ($P < 0.05$) (Table 4), indicating that Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles are effective as a gene vector. Interestingly, the efficiency of gene transfection using Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles is higher than that observed using liposomes ($P < 0.05$).

Absorption of Fe$_3$O$_4$-dextran-anti-β-HCG-GAPDH AS-ODN in different cells

The fluorescence intensity in JEG-3 and JAR cells is clearly higher than that observed in RL95-2, Hela, HepG2, and Lovo ($P < 0.05$) (Table 4), while there is little difference between the fluorescence intensity of JEG-3 and JAR cells ($P > 0.05$). These results indicate that Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles are more readily absorbed by choriocarcinoma cells.

Distribution of Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticles in nude mice

In groups I and II, iron content in choriocarcinoma hypodermal tumors was highest in heart, liver, spleen, lung, and kidney ($P < 0.05$). At the same time, it was found that Fe$^{3+}$ content in choriocarcinoma hypodermal tumors of group I was higher than that of group II ($P < 0.05$). In group III, the iron content in choriocarcinoma hypodermal tumors is less than that in liver or spleen ($P < 0.05$). These results indicate that when modified

### Table 1 Inhibitory rate of Fe$_3$O$_4$-dextran-anti-β-HCG nanoparticle to JEG-3 cells

| Control group | 18.75 (µg/mL) | 30 (µg/mL) | 37.5 (µg/mL) | 56.25 (µg/mL) | 75 (µg/mL) |
|---------------|---------------|------------|--------------|---------------|------------|
| A$_{570}$     | 0.374 ± 0.025 | 0.372 ± 0.031 | 0.368 ± 0.027 | 0.361 ± 0.023 | 0.310 ± 0.037 | 0.293 ± 0.034 |
| Inhibitory rate (%) | 0 | 0.5 | 1.6 | 3.5 | 17.1 | 21.7 |

**Abbreviations:** HCG, human chorionic gonadotropin; Fe$_3$O$_4$, magnetic iron oxide.
by β-HCG monoclonal antibody, Fe₃O₄ nanoparticles are able to target choriocarcinoma tumors and that magnetic fields can strengthen the targeting efficiency (Table 5).

### Discussion

Gene therapy is the insertion of genes into an individual’s cells and tissues to treat a disease. For hereditary diseases, the defective mutant allele is replaced with a functional allele. Antisense therapy is not strictly a form of gene therapy, but it is a genetically mediated therapy and is often used together with other methods. Using AS-ODNs to downregulate specific gene products requires oligonucleotides to enter cells and hybridize to the target messenger RNA present in the cytoplasm and/or nucleus. Nevertheless, the poor ability of oligonucleotides to cross the cell membrane and the degradation of oligonucleotides by DNase I greatly limit their potency. Therefore, it is necessary to identify a safe, effective, and stable gene vector.

The development of nanoparticle technology provides a new type of gene vector. Nanoparticles possess several advantages as gene vectors: 1) they are not biologic materials, so they should not induce immune responses; 2) unlike viral carriers, they have limited genotoxicity and cytotoxicity; 3) they can mediate the insertion of foreign genes into DNA of host chromosomes, and as a result, foreign genes are stably expressed; 4) they can protect foreign genes from complement and host enzymes; and 5) they can counteract or kill some viruses. With these advantages, nanoparticles have promise as gene vectors.

The feasibility and superiority of Fe₃O₄-dextran-anti-β-HCG nanoparticles as gene vector are discussed in the next section.

### Preparation and characterization of Fe₃O₄-dextran-anti-β-HCG nanoparticles

Dextran, FeCl₃, and FeCl₂ precipitate together under alkaline conditions. As a result, nanometer-sized dextran-coated iron oxide particles may be synthesized. The surface of dextran contains many hydroxyl groups. Once oxidized by NaIO₄, these hydroxyl groups can transform to aldehyde.

### Table 2: Transfection efficiency of anti-β-HCG monoclonal antibody bound to nanoparticle

| Antibody concentration (μg/mL) | Anti-β-HCG antibody (OD data) | Aldehyde nanoparticle (OD data) | Preservation rate (%) | Nonaldehyde nanoparticle (OD data) | Preservation rate (%) |
|--------------------------------|-----------------------------|-------------------------------|----------------------|-----------------------------------|----------------------|
| 150                            | 0.441                        | 0.385                         | 87.3                 | 0.058                             | 13.2                 |
| 100                            | 0.372                        | 0.341                         | 91.7                 | 0.050                             | 13.4                 |
| 80                             | 0.316                        | 0.282                         | 89.2                 | 0.041                             | 13.0                 |
| 50                             | 0.281                        | 0.253                         | 90.0                 | 0.039                             | 13.9                 |
| 10                             | 0.227                        | 0.208                         | 91.6                 | 0.031                             | 13.7                 |

**Abbreviations:** HCG, human chorionic gonadotropin; OD, optical density.

**Figure 2:** Immunofluorescence staining of A) aldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticles, B) anti-β-HCG antibody, and C) nonaldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle.

**Abbreviations:** Fe₃O₄, magnetic iron oxide; HCG, human chorionic gonadotropin.

**Figure 3** Electrophoresis of simple gAPDh AS-ODN (second track), nonaldehyde Fe₃O₄-dextran-anti-β-HCG-GAPDH AS-ODN (third track), aldehyde Fe₃O₄-dextran-anti-β-HCG-GAPDH AS-ODN (fourth track), and Fe₃O₄-dextran-anti-β-HCG nanoparticles (fifth track).

**Abbreviations:** GADPH, glyceraldehyde-3-phosphate dehydrogenase; AS-ODN, antisense oligodeoxynucleotides; Fe₃O₄, magnetic iron oxide; HCG, human chorionic gonadotropin.
Preparation and characterization of magnetic nanoparticles

Table 4 Fluorescence intensity in different cells

| Groups          | Fluorescence intensity |
|-----------------|------------------------|
| Jeg-3 cells     | 26.57 ± 2.38           |
| JAR cells       | 26.35 ± 2.27           |
| RL95-2 cells    | 17.24 ± 1.06           |
| Hela cells      | 16.91 ± 1.51           |
| HepG2 cells     | 13.26 ± 1.20           |
| Lovo cells      | 13.77 ± 1.18           |

Table 3 Fluorescence intensity of nanoparticle mixtures in Jeg-3 cells

| Groups                      | Fluorescence intensity |
|-----------------------------|------------------------|
| I. Control group            | 3.31 ± 0.37            |
| II. Fe₃O₄-dextran-anti-β-HCG nanoparticle complexes | 9.69 ± 0.81 |
| III. GAPDH AS-ODN           | 8.41 ± 0.72            |
| IV. Fe₃O₄-dextran-anti-β-HCG-GAPDH AS-ODN complexes | 26.57 ± 2.38 |
| V. Liposome-GAPDH AS-ODN    | 15.36 ± 1.25           |

**Biocompatibility of Fe₃O₄-dextran-anti-β-HCG nanoparticles**

Having a safe gene carrier is very important for gene therapy. Studies have confirmed that iron-containing fluids have favorable biocompatibility. Unutilized iron is discharged by skin, gallbladder, and kidney. The biocompatibility of Fe₃O₄ nanoparticles is improved further with a dextran coating.

In this study, it was found that when the concentration of Fe⁺ is <37.5 µg/mL, nanoparticles were not toxic to choriocarcinoma cells.

**Immunoreactivity of Fe₃O₄-dextran-anti-β-HCG nanoparticles**

It is important that the process of combining dextran-coated iron oxide nanoparticles with anti-β-HCG monoclonal antibody preserves the antibody activity. In this study, it was found that the transfection efficiency of anti-β-HCG monoclonal antibody activity in aldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle is higher than 85%, whereas the transfection efficiency of anti-β-HCG monoclonal antibody activity in nonaldehyde Fe₃O₄-dextran-anti-β-HCG nanoparticle is about 13%. This indicates that nonaldehyde dextran-coated iron oxide nanoparticles do not effectively bind to antibodies, although it is feasible for aldehyde dextran coat iron oxide nanoparticles to preserve antibody activity. To study the interactions between Fe₃O₄-dextran-anti-β-HCG nanoparticles and choriocarcinoma cells, indirect immunofluorescence was used. The results show that Fe₃O₄-dextran-anti-β-HCG nanoparticles can attach to choriocarcinoma cells tightly, indicating that these nanoparticles have excellent discrimination and potency with respect to choriocarcinoma cells.

**Capability of Fe₃O₄-dextran-anti-β-HCG nanoparticle as a gene vector**

The surface potential of Fe₃O₄-dextran nanoparticle is close to neutral, although the surrounding environment can
Table 5 Distribution of Fe₃O₄-dextran-anti-β-HCG nanoparticles in nude mice (mg/g)

| Group | Heart       | Liver       | Spleen      | Lung        | Kidney      | Choriocarcinoma tumor |
|-------|-------------|-------------|-------------|-------------|-------------|-----------------------|
| I     | 0.614 ± 0.05| 1.351 ± 0.16| 0.753 ± 0.07| 0.663 ± 0.04| 0.356 ± 0.02| 5.959 ± 0.38          |
| II    | 0.598 ± 0.05| 2.994 ± 0.19| 1.805 ± 0.15| 0.586 ± 0.05| 0.394 ± 0.03| 4.112 ± 0.39          |
| III   | 0.718 ± 0.09| 6.398 ± 0.65| 2.991 ± 0.24| 0.697 ± 0.07| 0.297 ± 0.02| 1.262 ± 0.11          |

Abbreviations: HCG, human chorionic gonadotropin; Fe₃O₄, magnetic iron oxide.

Figure 5 Theory of how Fe₃O₄-dextran-anti-β-HCG nanoparticles are prepared.

Abbreviations: Fe₃O₄, magnetic iron oxide; HCG, human chorionic gonadotropin; BSA, bovine serum albumin.
to all organs through blood flow. This will not only reduce the drug concentrations in diseased organs, but also cause side effects. Researchers are, therefore, doing their best to increase drug concentrations in diseased organs, while decreasing the drug concentrations in other organs. As a gene vector, nanoparticles are of interest because they can impact distribution of DNA in the body due to targeting capabilities. Nanoparticle targeting can be divided into passive targeting and active targeting.6

In passive targeting, nanoparticles are taken into the reticuloendothelial system, such as the liver, spleen, and lymph, which is beneficial to diseases of the reticuloendothelial system. However, when being used to treat tumors, nanoparticles are expected to assemble in the tumor itself, so the need to obtain active targeting becomes even more important. Active targeting is subdivided into physical, chemical, and biological targeting. Physical and chemical targeting are realized according to the pH, temperature, and magnetism of the nanoparticle, whereas biological targeting is realized according to the antigen and acceptor on the surface of nanoparticle.

To target choriocarcinomas, it is important to reduce the amount of nanoparticle that is absorbed by the reticuloendothelial system. Fe3O4-dextran-anti-β-HCG nanoparticles that possess magnetic- and immune-targeting capabilities were prepared. To demonstrate nanoparticle targeting, the absorption of Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN in different cells was tested. The transfection efficiency of Fe3O4-dextran-anti-β-HCG nanoparticles in choriocarcinoma JEG-3 and JAR cells was found to be much higher than that in RL95-2, Hela, HepG2, and Lovo cells. This indicates that anti-β-HCG monoclonal antibody in Fe3O4-dextran-anti-β-HCG nanoparticles combined specifically with β-HCG antigen in choriocarcinoma cells. In other words, these nanoparticles have characteristics of biological targeting. However, it was also found that when using magnetic and immune targeting together, Fe3O4-dextran-anti-β-HCG nanoparticles are absorbed into the target reticuloendothelial system and assemble in the choriocarcinoma tumor. Furthermore, the combined effect of magnetic and immune targeting is stronger than that of magnetic targeting or immune targeting alone.

**Conclusion**

In summary, Fe3O4-dextran-anti-β-HCG nanoparticles represent an appropriate vector for gene therapy and demonstrate strong resistance to degradation. They combine high transfection efficiency with good biocompatibility and low cytotoxicity. Because they can be targeted using magnetic and antibody recognition mechanisms, they offer the possibility for additional targeting strategies beyond those currently in use.

**Acknowledgment**

We greatly appreciate the National Hepatobiliary and Enteric Surgery Research Center for their help with the manuscript. This study was conducted at Xiangya Hospital, Central South University, Changsha, Hunan, China.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Pattinson SD. Regulating germ-line gene therapy to avoid sliding down the slippery slope. *Med Law Int*. 2000;4(3–4):213–222.
2. Xia H, Wei G, Jun L, et al. Preparation of nano-scaled magnetic biological probes of Fe3O4/dextran/antibody and chromatographic assay. *Gaodeng Xuejiao Huaxue Xuebao*. 2004;25(3):445–447.
3. Zelphati O, Szoka FC Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. *Pharm Res*. 1996;13(9):1367–1372.
4. Legrand V, Leissner P, Winter A, Mehtali M, Lusky M. Transductional targeting with recombinant adenovirus vectors. *Curr Gene Ther*. 2002;2(3):323–339.
5. Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review). *Int J Oncol*. 2002;21(3):461–468.
6. Zhang YD. *Nanobiotechnology*. Beijing, China: Scientific Publishing Company; 2005:1.
7. Lambert G, Fattal E, Couvreur P. Nanoparticle systems for the delivery of antisense oligonucleotides. *Adv Drug Deliv Rev*. 2001;47(1):99–112.
8. Wagner S, Schnorr J, Pilgrimm H, Hamm B, Taupitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging; preclinical in vivo characterization. *Invest Radiol*. 2002;37(4):167–177.
9. Lawaczek R, Bauer H, Frenzel T, et al. Magnetic iron oxide particles coated with carboxyldextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A. *Acta Radiol*. 1997;38(4 Pt 1):584–597.
10. Kneuer C, Sameti M, Haltner EG, et al. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. *Int J Pharm*. 1996;13(2):257–261.
11. Ogris M, Wagner E. Targeting tumors with non-viral gene delivery systems. *Drug Discov Today*. 2002;7(8):479–485.
12. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. *Pharm Res*. 2000;17(6):707–714.
13. Chavany C, Le Doan T, Couvreur P, Puisieux F, Hélène C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. *Pharm Res*. 1992;9(4):441–449.
14. Cui Z, Mumper RJ. Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation. *Bioconjug Chem*. 2002;13(6):1319–1327.
15. Nakada Y, Fattal E, Fouquié M, Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. *Pharm Res*. 1996;13(1):38–43.
16. Xiang JJ, Zhu SG, Lv HB, et al. Use of magnetic iron oxide nanoparticles as gene carrier. Chin J Cancer. 2001;20(10):1009–1014.
17. Xiang JJ, Tang JQ, Zhu SG, et al. IONP-PLL: a novel non-viral vector for efficient gene delivery. J Gene Med. 2003;5(9):803–817.
18. Rhaese S, von Briesen H, Rübsamen-Waigmann H, Kreuter J, Langer K. Human serum albumin-polyethylenimine nanoparticles for gene delivery. J Control Release. 2003;92(1–2):199–208.